Conference Information

Welcome Message

Ladies and gentlemen, pioneers and pathbreakers

As London timeless streets meet cutting-edge science in 2025, we invite you to be part of a gathering defined by action, not observation.

The 5th International Conference on Cancer Research and Treatment opens its doors to the thinkers, doers, and risk-takers who are reimagining the future of medicine. Over the next two days — August 20–21, 2025 — we won’t just exchange data or debate theories. Here, we’ll spark ideas, challenge the status quo, and carve new pathways for those whose lives depend on what we discover today.

This year theme, "Advances in Cancer: Turning Breakthroughs into Lifelines," is not just a title. It’s a promise. A commitment to push the boundaries of what’s possible in cancer care, to transform isolated achievements into global standards, and to turn fleeting victories into lasting lifelines for patients everywhere.

In the iconic city of London a place that has reinvented itself countless times. We invite you to do the same with your science, your practice, and your perspectives. Expect no routine lectures. Expect debates that unsettle you, ideas that invigorate you, and collaborations that outlive this conference.

We welcome not only your expertise but your curiosity, your bold questions, and your restless ambition to make things better.

Here is to redefining whats possible. Welcome aboard.

About

Join Us in London for Cancer 2025!

In a world where cancer research is evolving faster than ever, international collaboration remains the cornerstone of progress. This August 20–21, 2025, the city of London, UK will host a vibrant convergence of cancer specialists, scientists, and innovators for the 5th International Conference on Cancer Research and Treatment. It’s more than a meeting — it’s a platform where knowledge meets impact, and ideas turn into action.

Who Should Attend?

We welcome a diverse, global audience of:

Oncologists, Radiologists, Haematologists, Pathologists
Cancer Researchers, Clinical Trialists, Molecular Biologists
Pharmaceutical & Biotech Companies
Medical Device & Diagnostic Technology Firms
Healthcare Providers, Hospitals, and Cancer Centres
University Faculties & Academic Institutions
R&D Organisations, Start-ups, and Policy Makers
Medical Associations, Advocacy Groups & Industry Leaders

Why Attend?

Discover new solutions, technologies, and collaborative opportunities
Present your research on a global stage and network with leaders in oncology
Engage in thought-provoking discussions shaping the future of cancer care

Conference Highlights:

Keynote Addresses from global cancer research leaders
Symposia, Scientific Presentations & Panel Debates
Interactive Workshops, Poster Displays & Networking Mixers
Prestigious Awards, including:

Young Researcher Award
Best Oral Presentation
Best Scientific Poster
Keynote Excellence Award
Outstanding Committee Member Award

Theme for 2025:

Advanced Diagnostics and Imaging: Beyond Boundaries

Be part of a conference where ideas travel beyond borders and research drives tomorrow’s breakthroughs.

Join us in London this August and be at the heart of global cancer innovation.

Call For Abstracts

Call for Abstracts — Cancer 2025

The countdown is on! Present your research at the 5th International Conference on Cancer Research and Treatment on August 20–21, 2025.

Abstracts for papers and posters are now open.

Selection Criteria

Must align with conference themes: therapies, diagnostics, care models, or innovations.
Clear, concise, well-structured presentation.
Solid methodology and credible results.
Demonstrable potential to advance cancer care.
Unique or fresh perspectives.

Guidelines

Submit in Word format via our website.
Maximum 300 words.
Structure: Summary, Background, Methods, Results, Analysis, Conclusion.
Author bios (150 words max), headshots, and emails required.

Mark Your Calendar!

Abstract Submission Deadline: July 31, 2025
Final Paper Submission Deadline: August 08, 2025
Notification of Abstract Decision: Within 24 to 48 hrs
Early Bird Registration Closes: July 31, 2025

Sessions

Session 1: Cancer

This foundational session offers a comprehensive examination of cancer as a multifaceted biological disease. It will cover the cellular, genetic, and environmental factors contributing to oncogenesis and tumour progression. Speakers will address advances in molecular profiling and the impact of these findings on diagnosis and patient-specific treatment strategies.

Subtracks:

Cancer Pathogenesis & Molecular Pathways
Tumour Microenvironment and Signalling
Novel Cancer Biomarkers
Epidemiology and Prevention Strategies
Patient-Centred Cancer Care
Advances in Cancer Screening Methods

Discussions will include emerging global trends in cancer incidence and preventive oncology initiatives. Attendees will gain a holistic understanding of cancer's biological complexity and its implications for research and clinical care.

Related Conferences:

Related Associations:

American Association for Cancer Research (AACR) | American Society of Clinical Oncology (ASCO) | European Society for Medical Oncology (ESMO) | International Cancer Research Organization (ICRO) | American Society for Radiation Oncology (ASTRO) | American Association of Cancer Education (AACE) | European Association for Cancer Research and Treatment (EACR) | Society for Immunotherapy of Cancer (SITC) | National Comprehensive Cancer Network (NCCN) | Global Society of Oncology Pharmacy Practitioners (GSOPP)

Related Journals:

Cancer Discovery and Translational Research | Journal of Clinical and Experimental Oncology | European Review of Cancer Sciences | International Journal of Oncology and Hematology | Journal of Cancer Therapeutics and Precision Medicine | World Journal of Cancer Research & Clinical Practice | Advances in Surgical and Interventional Oncology | Cancer Metastasis and Molecular Pathology Insights | Asia-Pacific Cancer Prevention and Control Journal | Oncology Therapeutics and Innovations Review

Session 2: Chemotherapy & Drug Delivery

This session highlights recent advances in systemic cancer treatments, including novel chemotherapy protocols and combination regimens. It will feature insights into overcoming multidrug resistance and enhancing treatment efficacy with targeted delivery technologies.

Experts will present breakthroughs in nanocarrier systems, liposomal formulations, and localised intratumoral therapies. Emphasis will be placed on reducing toxicity and improving patient tolerability while maximising therapeutic outcomes. Case studies and clinical trial updates will support evidence-based discussions.

Subtracks:

Advances in Chemotherapy Regimens
Nanoparticle and Liposome-Based Delivery
Overcoming Multidrug Resistance
Pharmacokinetics & Pharmacodynamics in Oncology
Intratumoral Drug Delivery Techniques
Chemotherapy-Induced Toxicity Management

Related Journals:

Related Conferences:

Related Associations:

Session 3: Immuno-Oncology

Dedicated to the dynamic field of cancer immunotherapy, this session will explore immune checkpoint blockade, cellular therapies, and tumour microenvironment modulation. Experts will address the latest mechanisms of immune escape and resistance, along with biomarkers for therapy response prediction.

The session will spotlight novel combination strategies aimed at enhancing anti-tumour immunity and patient survival outcomes. Presentations will include updates on clinical trials, translational research, and regulatory perspectives. Interactive discussions will focus on challenges in integrating immunotherapy into clinical practice.

Subtracks:

Immune Checkpoint Blockade
Tumour-Infiltrating Lymphocyte Therapy
CAR-T and CAR-NK Therapies
Immunotherapy Combination Strategies
Immune-Related Adverse Events Management
Cancer Vaccine Development

Related Conferences:

Related Associations:

Related Journals:

Session 4: Breast Cancer

This session provides a focused exploration of advancements in breast cancer screening, diagnostics, and targeted therapies. It will discuss molecular classification, genetic risk assessment, and subtype-specific treatment protocols. Special attention will be given to innovations in imaging, reconstructive surgery, and novel systemic treatments like CDK4/6 inhibitors. Experts will examine patient-centred approaches, survivorship care, and quality of life considerations. Recent clinical trial outcomes and evolving global trends will also be reviewed.

Subtracks:

Triple-Negative Breast Cancer Advances
HER2-Targeted Therapies
Breast Imaging Innovations
Genetic Risk Assessment & BRCA Mutation Studies
Breast-Conserving and Reconstructive Surgery
Survivorship and Quality of Life

Related Journals:

Related Conferences:

Related Associations:

Session 5: Brain & CNS Tumors

This session delves into the complexities of diagnosing and managing central nervous system (CNS) tumours. Discussions will cover advancements in imaging modalities, surgical innovations, and molecular classification of primary and metastatic brain tumours.

Experts will address unique challenges in treating high-grade gliomas, paediatric brain tumours, and CNS metastases. The role of immunotherapy and novel drug delivery systems in overcoming the blood-brain barrier will be explored. Multidisciplinary care models and clinical trial data will inform evidence-based practice discussions.

Subtracks:

Glioma Biology and Treatment
Innovations in Neuroimaging
Blood-Brain Barrier Disruption Techniques
Paediatric Brain Tumour Management
CNS Metastasis Therapeutics
Neuro-Oncology Surgery

Related Conferences:

Related Associations:

Related Journals:

Session 6: Radiology

This session highlights the essential role of radiology in cancer detection, staging, treatment planning, and response assessment. Experts will present advances in imaging technologies, including AI-enhanced radiomics, theranostics, and molecular imaging.

Discussions will focus on improving diagnostic accuracy, reducing invasive procedures, and integrating imaging biomarkers into personalised oncology care. Emerging trends in image-guided interventions and AI-powered predictive analytics will be explored. The session aims to redefine imaging as a therapeutic tool alongside its diagnostic function.

Subtracks:

PET, MRI, and CT in Oncology
AI-Driven Cancer Imaging
Theranostics and Radiopharmaceuticals
Radiomics and Imaging Biomarkers
Image-Guided Tumour Ablation
Molecular Imaging in Cancer Detection

Related Journals:

Related Conferences:

Related Associations:

Session 7: Surgical Oncology

This session offers an in-depth examination of modern surgical techniques in cancer treatment, focusing on minimally invasive, robotic-assisted, and reconstructive surgeries. Experts will discuss perioperative management, tumour staging, and strategies for improving oncological and functional outcomes.

Subtracks:

Robotic and Minimally Invasive Cancer Surgery
Sentinel Node Mapping and Tumour Staging
Oncoplastic and Reconstructive Techniques
Surgery in Rare and Complex Tumours
Multidisciplinary Surgical Planning
Postoperative Recovery and Quality of Life

Emphasis will be placed on multidisciplinary tumour boards and integrating surgery with chemotherapy and radiotherapy. Innovations in tumour localisation, intraoperative imaging, and postoperative recovery protocols will also be covered. Case-based discussions will illustrate evidence-based surgical decision-making.

Related Conferences:

Related Associations:

Related Journals:

Session 8: Gene & Cell Therapy

Focusing on cutting-edge genetic and cellular approaches, this session will explore gene editing, adoptive cell transfer, and stem cell-based cancer therapies. Experts will discuss the application of CRISPR-Cas9, viral vectors, and non-viral systems for tumour-specific gene modifications.

Clinical updates on CAR-T and CAR-NK therapies will be presented, along with strategies to overcome immune evasion and tumour heterogeneity. Ethical and regulatory frameworks for gene and cell therapies will also be addressed. Real-world patient experiences and trial data will underpin discussions.

Subtracks:

CRISPR, TALEN, and Gene Editing in Oncology
Viral and Non-Viral Gene Delivery Systems
CAR-T and CAR-NK Cell Therapy Advances
Stem Cell-Based Therapeutics
Regulatory and Ethical Considerations
Overcoming Immune Escape in Solid Tumours

Related Journals:

Related Conferences:

Related Associations:

Session 9: Immunotherapy & Vaccines

This session explores immunotherapy innovations and therapeutic cancer vaccines as transformative strategies in oncology. Topics will include checkpoint inhibitors, adoptive T-cell therapies, tumour-specific vaccines, and immune modulators.

Experts will examine mechanisms of immune resistance and biomarker-driven personalisation of immunotherapies. Combination strategies to enhance efficacy and overcome limitations of monotherapies will be highlighted.

Subtracks:

Checkpoint Inhibitor Therapy Developments
Therapeutic Cancer Vaccines
Biomarkers for Immunotherapy Response
Combination Immunotherapy Strategies
Immune Escape and Resistance Mechanisms
T-cell Based Adoptive Immunotherapies

Related Conferences:

Related Associations:

Related Journals:

Session 10: Leukaemia & Blood Cancers

This session focuses on the clinical management and molecular underpinnings of haematologic malignancies including leukaemia, lymphoma, and multiple myeloma. Discussions will cover diagnostic innovations, risk stratification, and evolving therapeutic strategies, such as targeted agents and immunotherapies.

Case studies will illustrate management of minimal residual disease and treatment-resistant cases. Stem cell transplantation and cellular therapies will be explored as curative options in specific settings. The session will review recent guidelines and clinical trial outcomes.

Subtracks:

Acute and Chronic Leukaemia Management
Lymphoma Therapeutic Strategies
Multiple Myeloma Updates
Minimal Residual Disease Monitoring
Cellular Therapies in Haematologic Cancers
Stem Cell Transplantation Innovations

Related Journals:

Related Conferences:

Related Associations:

Session 11: Cell Metastasis: Mechanisms

This session examines the complex biological mechanisms driving cancer metastasis, from tumour cell invasion to colonisation of distant organs. Discussions will focus on epithelial-mesenchymal transition (EMT), angiogenesis, and interactions within the tumour microenvironment that facilitate metastasis.

Experts will present new insights into circulating tumour cells (CTCs) and exosome-mediated signalling. Innovative therapeutic targets aimed at halting metastasis progression will also be explored. Attendees will gain a deeper understanding of why metastasis remains the leading cause of cancer mortality.

Subtracks:

Epithelial-Mesenchymal Transition and Metastasis
Circulating Tumour Cells and Liquid Biopsy
Tumour Angiogenesis in Metastatic Spread
Organ-Specific Metastatic Mechanisms
Exosomes and Metastatic Niche Formation
Anti-Metastatic Drug Targets

Related Conferences:

Related Associations:

Related Journals:

Session 12: Targeted Cancer Therapies

This session highlights precision oncology’s growing role through targeted therapies that address specific genetic mutations and cellular pathways. Experts will discuss the latest approved targeted agents and ongoing clinical trials investigating kinase inhibitors, PARP inhibitors, and angiogenesis blockers.

Emphasis will be placed on resistance mechanisms and strategies to overcome them using combination therapies. Molecular diagnostics and companion testing will also be featured. Attendees will discover how these therapies are reshaping cancer care paradigms.

Subtracks:

Tyrosine Kinase Inhibitors in Solid and Haematologic Tumours
PARP Inhibitors in BRCA-Associated Cancers
Anti-Angiogenic Therapy
Mechanisms of Drug Resistance and Overcoming Strategies
Companion Diagnostics in Targeted Therapy
Emerging Targets in Rare and Aggressive Cancers

Related Journals:

Related Conferences:

Related Associations:

Session 13: Frontiers in Oncology Research

A visionary session spotlighting pioneering research directions and transformative breakthroughs in oncology. Experts will present studies on tumour genomics, novel biomarkers, and therapeutic resistance pathways.

Discussions will also cover liquid biopsies, organoid models, and tumour heterogeneity. The future of precision oncology, AI-driven analytics, and integrative medicine will be explored. This session aims to inspire collaborations that bridge basic research and clinical application.

Subtracks:

Liquid Biopsy and Circulating Biomarkers
Tumour Organoids and Preclinical Models
Novel Therapeutic Resistance Pathways
AI and Bioinformatics in Oncology Research
Cancer Epigenetics and Non-Coding RNAs
Emerging Molecular Targets

Related Conferences:

Related Associations:

Related Journals:

Session 14: Haematology in Oncology & Lymphatic System

This session covers the diagnosis and management of haematologic malignancies and disorders affecting the lymphatic system. Topics will include bleeding and clotting disorders in cancer patients, lymphomas, and rare haematologic neoplasms.

Discussions will explore advances in molecular diagnostics, immunotherapy, and transplant techniques. The session also addresses lymphoedema management and lymphatic metastasis. Case-based learning will reinforce evidence-based care pathways.

Subtracks:

Lymphoma Biology and Therapeutics
Coagulopathies in Oncology Patients
Haematopoietic Stem Cell Transplantation
Minimal Residual Disease in Blood Cancers
Immunotherapy in Haematologic Malignancies
Lymphoedema and Lymphatic Metastasis

Related Journals:

Related Conferences:

Related Associations:

Session 15: Cancer Pharmacology & Therapeutics

This session focuses on the pharmacological basis of cancer therapy, including mechanisms of drug action, pharmacokinetics, and toxicity profiles. Experts will discuss drug resistance, combination regimens, and pharmacogenomics in oncology. Emerging agents like antibody-drug conjugates (ADCs) and targeted kinase inhibitors will be featured. Case discussions will highlight the optimisation of dosing and therapeutic drug monitoring to improve clinical outcomes.

Subtracks:

Mechanisms of Action of Cancer Therapeutics
Pharmacogenomics in Oncology Drug Selection
Drug-Drug Interactions and Toxicity Management
Antibody-Drug Conjugates and Biologic Therapies
Therapeutic Drug Monitoring in Oncology
New Small Molecule and Kinase Inhibitors

Related Conferences:

Related Associations:

Related Journals:

Session 16: AI & Digital Oncology

A forward-looking session addressing the integration of artificial intelligence, machine learning, and digital health technologies in oncology. Topics include AI-powered imaging, predictive analytics, digital pathology, and patient monitoring platforms.

Experts will discuss ethical, regulatory, and data privacy concerns while highlighting real-world applications of digital tools in diagnosis, treatment, and clinical decision-making. This session aims to demystify AI and prepare oncologists for the future of data-driven cancer care.

Subtracks:

AI in Diagnostic Radiology and Pathology
Predictive Analytics for Patient Outcomes
Digital Twins and Virtual Patient Simulations
Wearable and Remote Monitoring in Cancer Care
Ethical AI Implementation in Oncology
AI in Clinical Trial Design and Recruitment

Related Journals:

Related Conferences:

Related Associations:

Session 17: Paediatric & Rare Cancers

Dedicated to addressing the unique biological, clinical, and psychosocial aspects of paediatric and rare cancers. This session will discuss molecular subtypes, genetic syndromes, and treatment-related challenges specific to these patient populations.

Emphasis will be placed on long-term survivorship, fertility preservation, and late effects of therapy. Experts will also explore research networks and collaborative initiatives essential for advancing care in these often-overlooked areas.

Subtracks:

Molecular Drivers in Paediatric Tumours
Rare Adult Cancers: Diagnosis and Management
Long-Term Survivorship and Late Effects
Fertility Preservation in Young Cancer Patients
Rare Tumour Registries and Research Networks
Paediatric CAR-T and Immunotherapy

Related Conferences:

Related Associations:

Related Journals:

Session 18: Palliative & Supportive Care

This session focuses on improving quality of life for cancer patients through comprehensive symptom management, psychosocial support, and integrative care models. Experts will present approaches for addressing emotional, spiritual, and family needs during the cancer journey. Palliative care integration into active treatment plans and survivorship care will also be explored.

Subtracks:

Pain and Symptom Management in Cancer
Psychosocial Oncology and Patient Counselling
Nutritional and Supportive Interventions
End-of-Life Care and Decision-Making
Integrative and Complementary Therapies
Palliative Care in Paediatric and Geriatric Oncology

Related Journals:

Related Conferences:

Related Associations:

Session 19: Emerging Trends in Cancer Genomics

This session highlights recent discoveries in cancer genomics, from driver mutations to tumour mutational burden and neoantigen prediction. Experts will discuss multi-omics approaches, epigenomics, and liquid biopsy applications. The session aims to translate genetic discoveries into actionable therapeutic strategies and personalised treatment plans. It will also explore the future of precision oncology driven by real-time genomic data.

Subtracks:

Tumour Genomic Profiling and Biomarker Discovery
Multi-Omics Approaches in Cancer Research
Liquid Biopsy for Real-Time Tumour Monitoring
Neoantigen Prediction for Personalised Immunotherapy
Cancer Epigenomics and Methylation Markers
AI in Genomic Data Interpretation

Related Conferences:

Related Associations:

Related Journals:

Session 20: Clinical Trials & Research

An essential session exploring the design, conduct, and analysis of oncology clinical trials. Discussions will address challenges in trial recruitment, adaptive trial designs, and real-world data integration.

Experts will share updates on pivotal oncology trials and regulatory landscapes. Emphasis will be placed on patient safety, ethical considerations, and strategies to improve diversity in trial participation.

Subtracks:

Adaptive and Basket Trial Designs
Real-World Data in Oncology Research
Ethical and Regulatory Aspects of Trials
Patient-Reported Outcomes in Clinical Trials
Challenges in Rare Cancer Trials
Digital Tools for Trial Management and Recruitment

Related Journals:

Related Conferences:

Related Associations:

Session 21: Others

Oncology Drug Discovery & Development
Preventive Oncology and Risk Reduction
Nutrition, Lifestyle & Cancer Care
Global Perspectives in Oncology
Next-Generation Oncology: Future Trends & Technologies
Nervous System Tumours and Management
Reproductive System Cancers
Digestive System Malignancies
Respiratory System Oncology
Urinary System Tumours
Musculoskeletal Cancers
Prostate & Genitourinary Cancers
Skin and Melanoma Research
Endocrine Tumours & Thyroid Oncology

Market Analysis

Global Market Overview

The global oncology market (combining diagnostics and treatment) was valued at USD 321.2 in 2024, projected to reach USD 903.8 by 2034, yielding a 10.9% CAGR
The cancer therapeutics sub-segment stood at $194.7 in 2024, expected to expand to USD 469.4 by 2034, at a 9.2% CAGR.

Regional Insights

North America leads the global oncology and cancer treatment market, holding a substantial 43–47% share. While growth remains steady, it's considered mature, with a CAGR of approximately 9.5%, fuelled by advances in immunotherapies, precision medicine, and favourable reimbursement policies.
Europe secures 25% of the market and is set for rapid growth at a 15.8% CAGR.
Asia-Pacific holds a 20% share, driven by:

Oncology therapy market growth at 11.2% CAGR (2025–2030).
Cancer treatment centre revenues rising from USD 17.4 in 2023 to USD 30.0B by 2030 (8.1% CAGR).

Middle East & Africa currently represent 5%, with healthcare infrastructure and accessibility steadily improving. Middle East & Africa, though holding a smaller share, is expected to grow at around 7.8% CAGR, fuelled by improving cancer care infrastructure, increased awareness, and expanding healthcare investments.

Treatment Technologies for Manufacturers

1. CAR T & Cell/Gene Therapies

CAR T therapies are a blockbuster trend, driven by high-priced, personalized treatments like Aucatzyl (Autolus)
Automated platforms (e.g., Cellares' “Cell Shuttle”) are enhancing scalable, cost-effective manufacturing
Gene therapies (CRISPR, viral vector-based) also growing at 12.5% CAGR by 2030

2. Immunotherapy and Antibody Drug Conjugates (ADCs)

Leading immunotherapy innovations are being propelled by developments in checkpoint inhibition, CAR T-cell approaches, and vaccine platforms.
ADCs offer precision targeting and reduced toxicity; over 50 companies are developing them

3. Radiotheranostics & Nanomedicine

Nanobiotixs NBTXR3 (hafnium oxide) amplifies radiotherapy on-going trials in multiple cancers
Terbium161 radiopharmaceuticals (e.g. VIOLET trial) show less than 50% PSA reduction with favourable side effects

4. Oncolytic Virus Therapies

Engineered viruses are gaining interest: the oncolytic virus market was USD 100 in 2022, forecasted at USD 615 by 2030 (25.5% CAGR)

5. Theranostics & Precision Delivery Tech

Theranostic platforms combining imaging and therapy (e.g. photodynamic + Raman) are showing promise
Nanoparticle-based drug delivery (smart targeting, reduced toxicity) is rapidly advancing.

6. 3D Bioprinting & Ex vivo Models

TissueTinker’s 3D-printed tumor replicas allow personalized drug testing and research

7. Sonodynamic & Photothermal Therapies

Sonodynamic therapy (ultrasound-activated drugs) is an emerging non-invasive approach.
Nanoparticles in photothermal/photodynamic therapy (light-triggered cancer cell ablation) are being explored.

Implications for Manufacturing Companies

Manufacturers can invest in:

Scalable cell/gene therapy platforms (automation, quality control systems).
Nanoparticle production for radioenhancers & targeted delivery.
Radiopharmaceutical facilities (e.g., Lutetium, Terbium isotope handling).
Bioreactors and 3D bioprinting hardware for personalized tumor models.
Contract R&D collaborations with biotech firms on ADCs, oncolytic viruses, theranostics.

Summary Table

Region	2024 Size	Market Forecast CAGR	Drivers
Global Oncology	USD 321	10.9%	Immunotherapy, precision medicine, diagnostics
Cancer Therapeutics	USD 194.7	9.2%	Targeted drugs, biologics
North America	47%	9.50%	R&D investment, infrastructure
Europe	25%	15.8%	Regulation, precision medicine
Asia-Pacific	20%	11.2%	Healthcare growth, generics
Middle East	5%	7.80%	Healthcare infrastructure & Accessibility

The cancer treatment landscape is evolving from bulk chemotherapy to high-precision, biologic-driven therapies, with manufacturing increasingly focused on personalization, nanotechnology, and theranostic integration.

Visa & Venue

Prime Venue in London, UK

We are excited to welcome you to Cancer Research and Treatment 2025 at a contemporary venue in central London, surrounded by the city's top attractions and historic landmarks.

Facilities Provided

Complimentary breakfast service
High-speed Wi-Fi access throughout the venue
Flexible check-in/check-out options (subject to availability)

Accommodation Choices

Single-occupancy rooms for personal space and rest
Double-occupancy rooms for shared stay with a colleague

Visa Assistance

Registered international attendees can request:
Official invitation letters
Acceptance letters for approved abstracts
Customized visa support letters
Documents issued via email to confirmed participants only.

Contact Us

For venue, visa, or event inquiries:

Whatsapp: +447389644903

5th International Conference on
Cancer Research and Treatment

Quick Links

Theme: Advances in Cancer: Turning Breakthroughs into Lifelines

Conference Information

Welcome Message

About

Call For Abstracts

Sessions

Market Analysis

Global Market Overview

Regional Insights

1. CAR T & Cell/Gene Therapies

3. Radiotheranostics & Nanomedicine

4. Oncolytic Virus Therapies

5. Theranostics & Precision Delivery Tech

6. 3D Bioprinting & Ex vivo Models

7. Sonodynamic & Photothermal Therapies

Implications for Manufacturing Companies

Summary Table

Visa & Venue